Agoura Hills biotech company A2 Biotherapeutics on Wednesday announced it has entered into a collaboration agreement with pharma giant Merck to further develop its cancer therapies.

According to the agreement, A2 will receive an unspecified upfront payment, as well as milestone payments and royalties on sales of any approved product. Equity investment and reimbursement of some expenses will be available to the Agoura Hills company.

Terms indicate A2 will continue its research and development of Tmod cell therapy to treat solid tumor cancers, and New Jersey-based Merck will help develop, manufacture and commercialize the cancer therapy once it pushes past Phase 1 clinical trials.


Subscribe to get the full story.

Are you a subscriber? Sign In